Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 104-110, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bowsher, R. R.
Right arrow Articles by Chance, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowsher, R. R.
Right arrow Articles by Chance, R. E.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1999;45:104-110.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Sensitive RIA for the Specific Determination of Insulin Lispro

Ronald R. Bowsher1,a, Renee A. Lynch1, Patricia Brown-Augsburger1, Paula F. Santa1, William E. Legan1, James R. Woodworth2 and Ronald E. Chance3

1 Departments of Drug Disposition,
2 Bioavailability and Pharmacokinetics, and
3 Protein Optimization, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285.
a Author for correspondence. Fax 317-277-9065; e-mail bowsher_ronald_r{at}lilly.com.

Insulin lispro is an insulin analog in which the primary sequence has been altered by the inversion of amino acids B28 and B29. To date, it has not been possible to specifically measure insulin lispro in the presence of endogenous insulin because of the high degree of homology between these peptides. However, the specific determination of insulin lispro offers advantages over quantifying total concentrations of immunoreactive insulin. We therefore immunized guinea pigs and screened for antibodies with increased affinity and selectivity for insulin lispro. We prepared a monospecific antiserum by a novel immunoadsorption strategy using despentapeptide insulin. The antiserum was used to develop a competitive RIA for insulin lispro. The RIA has a low limit of quantification (17.2 pmol/L); has no interference from insulin, proinsulin, or C-peptide; and has interassay CVs of 2.6–13.4%. The new RIA is useful for measuring serum concentrations of insulin lispro.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Moriyama, N. Hayashi, C. Ohyabu, M. Mukai, S. Kawano, and S. Kumagai
Performance Evaluation and Cross-Reactivity from Insulin Analogs with the ARCHITECT Insulin Assay,
Clin. Chem., July 1, 2006; 52(7): 1423 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. E. Owen and W. L. Roberts
Cross-Reactivity of Three Recombinant Insulin Analogs with Five Commercial Insulin Immunoassays
Clin. Chem., January 1, 2004; 50(1): 257 - 259.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. S. Apple, M. Murakami, M. Panteghini, R. H. Christenson, F. Dati, J. Mair, and A. H.B. Wu
International Survey on the Use of Cardiac Markers
Clin. Chem., March 1, 2001; 47(3): 587 - 588.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Sapin, V. Le Galudec, F. Gasser, M. Pinget, and D. Grucker
Elecsys Insulin Assay: Free Insulin Determination and the Absence of Cross-Reactivity with Insulin Lispro,
Clin. Chem., March 1, 2001; 47(3): 602 - 605.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.